All Stories

  1. Exploring Copy Number Variants in a Cohort of Children Affected by ADHD: Clinical Investigation and Translational Insights
  2. Clinical and Behavioral Correlates of Blood Acylcarnitine Profiles in Children with Autism Spectrum Disorder: A Cross-Sectional Analysis
  3. Acute transient psychotic episode as presenting sign of Mucopolysaccharidosis III A (Sanfilippo Syndrome type A) in an adolescent patient
  4. POLR3A rare variants in a patient with intellectual disability, ataxic gait and cortical malformations: a case-report
  5. Glycosylation Pathways Targeted by Deregulated miRNAs in Autism Spectrum Disorder
  6. Impaired myoblast differentiation and muscle IGF‐1 receptor signaling pathway activation after N‐glycosylation inhibition
  7. Correction: The Griffiths Autism Early Screening (GAES): A Novel Developmental Test for Screening Autism Spectrum Disorder
  8. Paroxysmal Dystonic Posturing Mimicking Nocturnal Leg Cramps as a Presenting Sign in an Infant with DCC Mutation, Callosal Agenesis and Mirror Movements
  9. Instrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis
  10. Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG
  11. The Griffiths Autism Early Screening (GAES): A Novel Developmental Test for Screening Autism Spectrum Disorder
  12. Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
  13. Higher frequency of TMEM199-CDG in the southern mediterranean area is associated with c.92G>C (p.Arg31Pro) mutation
  14. Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
  15. Copy Number Variations in Children with Tourette Syndrome: Systematic Investigation in a Clinical Setting
  16. PARK2 microdeletion in a multiplex family with autism spectrum disorder
  17. Early Sensory Profile in Autism Spectrum Disorders Predicts Emotional and Behavioral Issues
  18. Sensory Profiles in School-Aged Children with Autism Spectrum Disorder: A Descriptive Study Using the Sensory Processing Measure-2 (SPM-2)
  19. Defective IGF-1 prohormone N-glycosylation and reduced IGF-1 receptor signaling activation in congenital disorders of glycosylation
  20. Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study
  21. COG6‐CDG : Novel variants and novel malformation
  22. Active site variants in STT3A cause a dominant type I congenital disorder of glycosylation with neuromusculoskeletal findings
  23. Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data
  24. Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?
  25. N-Glycomics of Human Erythrocytes
  26. Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients
  27. Clinical, molecular and glycophenotype insights in SLC39A8-CDG
  28. N-Glycomics of Human Erythrocytes
  29. Psychometric Properties of the Italian Version of the Assessment of Identity Development in Adolescence (AIDA)
  30. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder
  31. Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis
  32. Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG)
  33. A Novel Homozygous <b><i>ALG12</i></b> Mutation in a Patient with CDG Type Ig: New Report of a Case with a Mild Phenotype
  34. Incidence of Autism Spectrum Disorder in Youths Affected by Gilles de la Tourette Syndrome Based on Data from a Large Single Italian Clinical Cohort
  35. Self- and Parent-Reported Psychological Symptoms in Young Cancer Survivors and Control Peers: Results from a Clinical Center
  36. Epilepsy and movement disorders in CDG : Report on the oldest‐known MOGS‐CDG patient
  37. International consensus guidelines for phosphoglucomutase 1 deficiency ( PGM1‐CDG ): Diagnosis, follow‐up, and management
  38. HILIC-UPLC-MS for high throughput and isomeric N-glycan separation and characterization in Congenital Disorders Glycosylation and human diseases
  39. Potential Associations Among Alteration of Salivary miRNAs, Saliva Microbiome Structure, and Cognitive Impairments in Autistic Children
  40. COVID-19 Pandemic Outbreak and its Psychological Impact on Patients with Rare Lysosomal Diseases
  41. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG)
  42. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG
  43. Disentangling Restrictive and Repetitive Behaviors and Social Impairments in Children and Adolescents with Gilles de la Tourette Syndrome and Autism Spectrum Disorder
  44. Clinical correlates in children with autism spectrum disorder and CNVs: Systematic investigation in a clinical setting
  45. Aberrant Sialylation in a Patient with a <i>HNF1α</i> Variant and Liver Adenomatosis
  46. Metal and essential element levels in hair and association with autism severity
  47. ALG12-CDG: novel glycophenotype insights endorse the molecular defect
  48. Adjunct Diagnostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy: A Pilot Study
  49. Diagnostic and Prognostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy
  50. Hyperkinetic movement disorders in congenital disorders of glycosylation
  51. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up
  52. SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
  53. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
  54. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
  55. Online comprehension across different semantic categories in preschool children with autism spectrum disorder
  56. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients
  57. CSF N-Glycoproteomics Using MALDI MS Techniques in Neurodegenerative Diseases
  58. International clinical guidelines for the management of phosphomannomutase 2‐congenital disorders of glycosylation: Diagnosis, treatment and follow up
  59. A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses
  60. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
  61. Expanded Newborn Screening Using Tandem Mass Spectrometry: Seven Years of Experience in Eastern Sicily
  62. KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature
  63. Study on the Role of Polymorphisms of the SOX-6 and MYB Genes and Fetal Hemoglobin Levels in Sicilian Patients with β-Thalassemia and Sickle Cell Disease
  64. CSF N-Glycomics Using MALDI MS Techniques in Alzheimer’s Disease
  65. Errata Corrige, Thalassemia Reports 2017; 7:6392
  66. Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder
  67. An Eye Tracker based Computer System to Support Oculomotor and Attention Deficit Investigations
  68. MALDI-MS profiling of serumO-glycosylation andN-glycosylation in COG5-CDG
  69. Granulocyte–Colony Stimulating Factor plus Plerixafor in Patients with β-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ Cells with Specific Gene Expression Profile
  70. Familial 18q12.2 deletion supports the role of RNA-binding protein CELF4 in autism spectrum disorders
  71. Early-Onset Epileptic Encephalopathy in infants with different forms of Congenital Disorders of Glycosylation (CDG)
  72. Prominent neurological involvement in Dercum disease
  73. Unusual Neurological Presentation of Nevoid Basal Cell Carcinoma Syndrome (Gorlin-Goltz Syndrome)
  74. Response to Alpha-Interferon Treatment of the Congenital Dyserythropoietic Anemia type I in Two Sicilian Beta Thalassemia Carriers
  75. ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients
  76. New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia
  77. CSF N-glycoproteomics for early diagnosis in Alzheimer's disease
  78. Electroclinical features of a patient with GLUT1 deficiency syndrome and adult onset periodic weakness
  79. Congenital Dyserythropoietic Anemias: Molecular Diagnosis and Diagnostic Approach in a Cohort of Italian Patients
  80. Miglustat Does Not Prevent Neurological Involvement in Niemann Pick C Disease
  81. Defective CSF sialylation in autism spectrum disorders
  82. Optimizing the Molecular Diagnosis of GALNS: Novel Methods to Define and Characterize Morquio-A Syndrome-Associated Mutations
  83. Electroclinical Features of Early-Onset Epileptic Encephalopathies in Congenital Disorders of Glycosylation (CDGs)
  84. Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial
  85. Familial 1q22 microduplication associated with psychiatric disorders, intellectual disability and late-onset autoimmune inflammatory response
  86. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation
  87. Development and Recent Progresses of Gene Therapy for β-Thalassemia
  88. Congenital Disorders of Glycosylation with Emphasis on Cerebellar Involvement
  89. Report of Two Never Treated Adult Sisters with Aromatic l-Amino Acid Decarboxylase Deficiency: A Portrait of the Natural History of the Disease or an Expanding Phenotype?
  90. First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major
  91. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major
  92. Imaging findings of mucopolysaccharidoses: a pictorial review
  93. Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death
  94. Phenotypic spectrum and prevalence of INPP5E mutations in Joubert Syndrome and related disorders
  95. Eye-tracking evaluation of ocular motility in Pompe disease
  96. Hurler disease (MPS IH): Evidence for the need of increased awareness by caring non-metabolic physicians
  97. DPM2-CDG: A muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy
  98. Glycomics of pediatric and adulthood diseases of the central nervous system
  99. An unknown cause of aortic valve stenosis: polycythemia vera
  100. Early Miglustat Therapy in Infantile Niemann-Pick Disease Type C
  101. Phenotypic heterogeneity in hereditary motor neuropathy type V: a new case report series
  102. Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera
  103. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene
  104. Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?
  105. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy
  106. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation
  107. Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G>A (p.Gly41Ser) mutation
  108. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab
  109. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study
  110. Secondary disorders of glycosylation in inborn errors of fructose metabolism
  111. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms
  112. Mucopolysaccharidosis VI: the Italian experience
  113. Mass spectrometry in the characterization of human genetic N‐glycosylation defects
  114. Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS
  115. Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia
  116. Inter- and intrafamilial variability in mucolipidosis II (I-cell disease)
  117. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease
  118. Chitotriosidase and Alzheimers Disease
  119. Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype)
  120. Intrathecal chitotriosidase and the outcome of multiple sclerosis
  121. Substrate reduction therapy in the infantile form of Tay-Sachs disease
  122. Callosal anomalies with interhemispheric cyst: Expanding the phenotype
  123. Congenital Insensitivity to Pain with Anhidrosis (NTRK1 Mutation) and Early Onset Renal Disease: Clinical Report on Three Sibs with a 25-Year Follow-Up in One of Them
  124. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia
  125. Chitotriosidase activity in colostrum from African and Caucasian women
  126. Chitotriosidase in Patients with Acute Ischemic Stroke
  127. Human aldolase A natural mutants: relationship between flexibility of the C-terminal region and enzyme function
  128. Startle epilepsy complicating aspartylglucosaminuria
  129. A Novel Exon 1 Mutation in a Patient with Atypical Lafora Progressive Myoclonus Epilepsy Seen as Childhood‐onset Cognitive Deficit
  130. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions
  131. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers
  132. Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation
  133. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria
  134. Plasma chitotriosidase activity in patients with ?-thalassemia
  135. Plasma Chitotriosidase Activity in Acute Plasmodium falciparum Malaria
  136. Mutation analysis of the MECP2 gene in patients with Rett syndrome
  137. White matter changes mimicking a leukodystrophy in a patient with Mucopolysaccharidosis: characterization by MRI
  138. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease
  139. Extraneurologic symptoms as presenting signs of Sanfilippo disease
  140. Plasma chitotriosidase activity in β-thalassemia major: a comparative study between Sicilian and Sardinian patients
  141. Plasma Chitotriosidase Activity Is a Marker of Recovery in Transplanted Patients Affected by β-Thalassemia major
  142. Arthrogryposis Multiplex Congenita and Pituitary Ectopia. A Case Report
  143. β-Hexosaminidase, α-d-mannosidase, and β-mannosidase expression in serum from patients with carbohydrate-deficient glycoprotein syndrome type I
  144. Tuberous breast deformity in an adolescent girl with Hurler-Scheie syndrome
  145. Carbohydrate-deficient glycoprotein syndromes: The Italian experience
  146. Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I
  147. Extraordinary bone involvement in a Gaucher disease type I patient
  148. Clinical and Neuroradiological Follow-Up in Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
  149. Peripheral lymphocyte subsets and other immune aspects in rett syndrome
  150. Point Mutations Throughout the GLI3 Gene Cause Greig Cephalopolysyndactyly Syndrome
  151. Rett Syndrome: Photographic Evidence of Rapid Regression
  152. Developmental patterns and neuropsychological assessment in patients with carbohydrate-deficient glycoconjugate syndrome type IA (phosphomannomutase deficiency)
  153. Plasma Chitotriosidase Activity in Patients with β-Thalassemia
  154. Lysosomal enzyme activities in serum and leukocytes from patients with carbohydrate-deficient glycoprotein syndrome type IA (phosphomannomutase deficiency)
  155. Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type I isoelectrofocusing pattern of serum sialotransferrins
  156. Two new mild homozygous mutations in Gaucher disease patients: Clinical signs and biochemical analyses
  157. Carbohydrate deficient glycoprotein (CDG) syndrome type I.
  158. Evidence for Genetic Heterogeneity in the Carbohydrate-Deficient Glycoprotein Syndrome Type I (CDG1)
  159. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes
  160. Familial Dandy-Walker variant in CDG syndrome
  161. Haemostatic Studies in Carbohydrate-deficient Glycoprotein Syndrome Type I
  162. Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I
  163. Pancreatitis and organic acidemias
  164. Carbohydrate deficient glycoprotein syndrome type I: ophthalmic aspects in four Sicilian patients.